High-Intensity Interval Training for Stage I-III Breast Cancer Patients

Stage IIIA Breast Cancer Clinical Trial

Official title:

High-Intensity Interval Training (HIT) for Breast Cancer Patients During Trastuzumab Use

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02454777
• Other study ID #: 1B-14-5
• Secondary ID: NCI-2015-005791B
• Status: Terminated
• Phase: N/A
• Start date: September 29, 2015
• Est. completion date: July 15, 2019

Study information

• Verified date: April 2021
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized pilot clinical trial studies the feasibility of high-intensity interval training in improving cardiovascular fitness in patients with stage I-III breast cancer undergoing chemotherapy with trastuzumab. Trastuzumab helps patients live longer, but may cause side effects to the heart. Aerobic exercise may help the heart function better, which may help protect it against side effects from trastuzumab. Exercise may also help reduce fatigue and prevent cancer from coming back. High-intensity interval training involves short bursts of higher intensity efforts with longer periods of recovery. This may also allow patients who cannot exercise for a long period of time to still be physically active. This trial studies whether patients can tolerate high-intensity interval training, and how well it works in improving fitness in patients with breast cancer receiving trastuzumab.

Description:

PRIMARY OBJECTIVES: I. To assess the feasibility (completion of > 80% exercise sessions) of utilizing high-intensity interval training (HIT). II. To determine the effects of HIT on aerobic exercise adaptation when compared to delayed group. III. To examine the effects of HIT on left ventricular function when compared to delayed group. IV. To determine the effects of HIT on endothelial function, arterial stiffness, and vascular atherosclerosis when compared to delayed group. OUTLINE: Participants are randomized to 1 of 2 groups. ARM I: HIT (High-intensity Interval Training) group - Participants undergo HIT over 30 minutes, thrice weekly for 8 weeks. ARM II: DEL (Delayed/usual care) group - Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT exercise program as in Arm I. After completion of study, patients are followed up at weeks 9 and 17.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: July 15, 2019
• Est. primary completion date: July 15, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• English or Spanish speaking
• Diagnosed with early stage (I-III) breast cancer, without evidence of metastatic disease
• Planned (neo)adjuvant therapy with trastuzumab (Herceptin) and/or anthracycline-based chemotherapy
• Not currently pregnant or planning to become pregnant throughout the duration of cancer treatment
• Physician (oncologist) clearance to participate in exercise at moderate to high intensity
• Have read and signed study informed consent document (ICF)
• EXERCISE INCLUSION CRITERIA:
• Normal body temperature (=< 100 degrees F)
• Resting blood pressure and/or heart rate within normal limits
• Participants have not received intravenous or oral chemotherapy on the same day and prior to scheduled exercise session

Exclusion Criteria:

• Advanced stage (stage IV) or metastatic breast cancer diagnosis (screening for metastases with scans only needed if there is clinical suspicion for metastases)
• Medical history of coronary heart or artery disease, chronic or acute congestive heart failure or history of systolic or diastolic insufficiencies
• Uncontrolled hypertension or other uncontrolled chronic disease (e.g. diabetes mellitus, thyroid disease, pulmonary disease, etc.)
• Moderate to highly active level of physical activity (e.g. currently participating in >= 60 minutes of moderate aerobic activity weekly)
• Orthopedic or other restrictions or contraindications to high-intensity (cycling) exercise
• EXERCISE EXCLUSION CRITERIA:
• Presence of fever (>= 100 degrees F)
• Resting blood pressure and/or heart rate outside normal limits
• Participants have received intravenous or oral chemotherapy on the same day and prior to scheduled exercise session

Related Conditions & MeSH terms

• Breast Neoplasms
• Stage IA Breast Cancer
• Stage IB Breast Cancer
• Stage IIA Breast Cancer
• Stage IIB Breast Cancer
• Stage IIIA Breast Cancer
• Stage IIIB Breast Cancer
• Stage IIIC Breast Cancer

Intervention

Behavioral:
• Exercise Intervention
Undergo HIT

Other:
• Laboratory Biomarker Analysis
Correlative studies
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	USC / Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of utilizing HIT under clinical trial conditions, assessed using participant attendance rate	The exercise program will be considered feasible if participants complete greater than 80% of exercise sessions. Participant attendance rates will be used to establish compliance and will be used to provide a perspective on how and to what extent cancer patients will participate in an experimental exercise intervention and what variations in exercise intensities may be tolerated. Feasibility will be assessed based on both program attendance as well as exercise time completed.	Up to 17 weeks
Secondary	Change in aerobic exercise adaptation measured by the maximum volume of oxygen uptake (VO2peak) (ml/kg/min)	A mixed-effect regression model will be fit to compare the mean changes in VO2peak (ml/kg/min) between groups. The effect of other covariates such as the menopausal age, severity of disease and the class of chemotherapy treatment and compliance rate on VO2peak (ml/kg/min) over time will also be examined.	Baseline to up to week 17
Secondary	Change in left ventricular function	A mixed-effect model will be fit to compare the mean changes in left ventricular ejection fraction, left ventricular end-diastolic volume, left ventricular end-systolic volume, and peak filling time. The effect of other covariates such as the menopausal age, severity of disease and the class of chemotherapy treatment and compliance rate on left ventricular function over time will also be examined.	Baseline to up to week 17